Sec. 7. Naloxone demonstration grants
706 words·~3 min read·
/bill/114/hr/2805/ih/section-7A research copy — for the controlling text, always check the official state or federal source. Not legal advice.
In this section— the term eligible entity means a State, a unit of local government, or a tribal government; the term first responder includes firefighters, law enforcement officers, paramedics, emergency medical technicians, and other individuals (including employees of legally organized and recognized volunteer organizations, whether compensated or not), who, in the course of professional duties, respond to fire, medical, hazardous material, or other similar emergencies; and the term opioid overdose reversal drug means a drug that, when administered, reverses in whole or part the pharmacological effects of an opioid overdose in the human body.
The Attorney General, in coordination with the Secretary of Health and Human Services and the Director of the Office of National Drug Control Policy, may make grants to eligible entities to create not more than 8 demonstration programs to allow properly trained first responders to prevent prescription opioid and heroin overdose death by administering an opioid overdose reversal drug to an individual who has experienced overdose or who has been determined to have likely experienced overdose.
To be eligible to receive a grant under this section, an entity shall submit an application to the Attorney General, at such time, in such manner, and accompanied by such information as the Attorney General shall require, and— that meets the criteria for selection under paragraph (2); and that describes— the evidence-based methodology and outcome measures that will be used to evaluate the program funded with a grant under this section, and specifically explain how such measurements will provide valid measures of the impact of the program; how the program could be broadly replicated if demonstrated to be effective; how the eligible entity will coordinate with their corresponding State substance abuse agency to identify protocols and resources that are available to victims and families, including information on treatment and recovery resources; and how the demonstration program will continue with State, local, or private funding after the expiration of the grant.
The Attorney General may award grants to eligible entities that demonstrate an institutional need for technical support and lack existing infrastructure in order to implement and train first responders to carry out a demonstration program under paragraph (b). In awarding grants under this section, the Attorney General shall give priority to an eligible entity located in a State that provides civil liability protection for first responders administering an opioid overdose reversal drug to counteract opioid overdoses by— enacting legislation that provides such civil liability protection; and providing a certification by the attorney general of the State that the attorney general has— reviewed any applicable civil liability protection law to determine the applicability of the law with respect to first responders who may administer an opioid overdose reversal drug to individuals reasonably believed to be suffering from opioid overdose; and concluded that the law described in subparagraph
(A)provides adequate civil liability protection applicable to such persons. An eligible entity shall use a grant received under this section to— make an opioid overdose reversal drug, which may include naloxone, available to be carried and administered by first responders; train and provide resources for first responders, on carrying and administrating such opioid overdose reversal drug for the prevention of prescription opioid and heroin overdose deaths; and establish processes, protocols, and mechanisms for referral to treatment. The Attorney General shall provide individualized technical support, as requested, to grant recipients under this section to assist with implementation of the demonstration program. A demonstration project grant shall be for a period of 3 years. Following the first grant year, a recipient of a grant awarded under this section shall report to the Attorney General on an annual basis — the number of first responders equipped with an opioid overdose reversal drug for the prevention of fatal prescription opioid and heroin overdose; the number of prescription opioid and heroin overdoses reversed by first responders; the number of calls for service related to prescription opioid and heroin overdose; and the extent to which overdose victims and families receive information about treatment services and available data describing treatment admissions. The Attorney General shall submit an annual report to the appropriate committees of Congress aggregating the data received from the grant recipients and evaluating the outcomes achieved by the demonstration projects funded under this section.